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Cancer is believed to arise primarily through accu-
mulation of genetic mutations. Although induced
pluripotent stem cell (iPSC) generation does not
require changes in genomic sequence, iPSCs ac-
quire unlimited growth potential, a characteristic
shared with cancer cells. Here, we describe a murine
system in which reprogramming factor expression
in vivo can be controlled temporally with doxycycline
(Dox). Notably, transient expression of reprogram-
ming factors in vivo results in tumor development
in various tissues consisting of undifferentiated
dysplastic cells exhibiting global changes in DNA
methylation patterns. The Dox-withdrawn tumors
arising in the kidney share a number of characteris-
tics with Wilms tumor, a common pediatric kidney
cancer. We also demonstrate that iPSCs derived
from Dox-withdrawn kidney tumor cells give rise to
nonneoplastic kidney cells in mice, proving that
they have not undergone irreversible genetic trans-
formation. These findings suggest that epigenetic
regulation associated with iPSC derivation may drive
development of particular types of cancer.
INTRODUCTION
Induced pluripotent stem cells (iPSCs) can be established from
differentiated somatic cells by the forced induction of four
transcription factors: Oct3/4, Klf4, Sox2, and c-Myc (Takahashi
et al., 2007; Takahashi and Yamanaka, 2006; Maherali et al.,
2007; Okita et al., 2007; Wernig et al., 2007; Woltjen et al.,
2009). To achieve somatic cell reprogramming, multiple cellularprocesses act synergistically in a sequential manner (Brambrink
et al., 2008; Polo et al., 2012; Samavarchi-Tehrani et al., 2010).
Despite extensive studies, the precise mechanism of somatic
cell reprogramming still remains unclear (Rais et al., 2013). It is
known that non-iPSC-like colonies often appear at the interme-
diate stage of cellular reprogramming in vitro. In addition, there
are several reports describing partial iPSCs that deviate suc-
cessful reprogramming (Fussner et al., 2011; Mikkelsen et al.,
2008; Sridharan et al., 2009). However, the characteristics of
such failed reprogramming states are largely unknown, and no
study has elucidated the failed reprogramming state from cell
types other than fibroblasts.
The process of iPSC derivation shares many characteristics
with cancer development. During reprogramming, somatic
differentiated cells acquire the properties of self-renewal along
with unlimited proliferation and exhibit global alterations of the
transcriptional program, which are also critical events during
carcinogenesis (Ben-Porath et al., 2008). The metabolic switch
to glycolysis that occurs during somatic cell reprogramming is
similarly observed in cancer development (Folmes et al., 2011).
Such similarities suggest that reprogramming processes and
cancer development may be partly promoted by overlapping
mechanisms (Hong et al., 2009). Practically, the forced induction
of the critical reprogramming factorOct3/4 in adult somatic cells
results in dysplastic growth in epithelial tissues through the
inhibition of cellular differentiation in a manner similar to that in
embryonic cells (Hochedlinger et al., 2005). These studies pro-
vided a possible link between transcription-factor-mediated
reprogramming and cancer development.
To elucidate the involvement of failed reprogramming in can-
cer development, in the present study, we generated an in vivo
reprogramming mouse system using reprogramming factor-
inducible alleles and examined the effects of reprogramming
factor expression in somatic cells in vivo. We show that failed
reprogramming-associated cells behave similarly to cancer cellsCell 156, 663–677, February 13, 2014 ª2014 Elsevier Inc. 663
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Figure 1. Reprogramming of Somatic Cells In Vivo
(A) Generation of four-factor-inducible ESCs. TetOP, tetracycline-dependent promoter.
(B) Generation of chimeric mice using OSKM-inducible ESCs. mCherry signals could be detected in various organs after Dox treatment for 3 days.
(C) Treatment of chimeric mice with Dox for 28 days resulted in the development of multiple tumors containing pluripotent stem cells. (a) A representative
macroscopic image of the cut surface of the kidney tumor. (b) A histological section of the kidney tumor showing the differentiation of tumor cells into three
germ layers, indicating teratoma formation. The blue, red, and black arrows represent neuronal, cartilage, and glandular epithelial components, respectively.
Scale bar, 200 mm.
(legend continued on next page)
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and cause neoplasia resembling Wilms tumor, a childhood
blastoma in the kidney. Moreover, we demonstrate that altered
epigenetic regulations cause the abnormal growth of such failed
reprogramming-associated cancer cells.
RESULTS
In Vivo Reprogrammable Mouse
To establish the reprogrammable mouse system, we generated
embryonic stem cells (ESCs) in which reprogramming factors
can be induced under the control of doxycycline (Dox) (Fig-
ure 1A) (Carey et al., 2010; Stadtfeld et al., 2010b). We used
KH2 ESCs with the optimized reverse tetracycline-dependent
transactivator at the ROSA 26 locus (Beard et al., 2006). A
polycistronic cassette encoding four reprogramming factors
(Oct3/4, Sox2, Klf4, and c-Myc) (Carey et al., 2010), followed
by ires-mCherry, was targeted into the Col1a1 gene locus
under the tetracycline-dependent promoter of KH2 ESCs
(Figure 1A).
Next, we generated chimeric mice via blastocyst injection
of four-factor (4F)-inducible ESCs. To confirm inducible ex-
pression of the reprogramming factors and mCherry in vivo,
Dox-containing water was provided to chimeric mice starting
at 4 weeks of age. On day 3 of Dox treatment, we could detect
the mCherry signal in various organs, including stomach, intes-
tine, liver, pancreas, kidney, gallbladder, and skin (Figure 1B).
We also confirmed the expression of reprogramming factors in
germline-transmitted mouse tissues by quantitative RT-PCR
(qRT-PCR) (Figure S1A available online).
Mouse embryonic fibroblasts (MEFs) containing these reprog-
ramming factor-inducible alleles could give rise to iPSCs after
Dox treatment in vitro (Figure S1B). We next asked whether
responding somatic cells could be reprogrammed in vivo. The
chimeric and germline-transmitted mice given Dox-containing
water (2 mg/ml) from 4 weeks of age became morbid within
7–10 days and a few days, respectively. A small proportion of
chimeric mice could be treated with Dox for 4 weeks, presum-
ably because of a lower contribution of ESCs in responding
tissues. Notably, mice treated with Dox for 4 weeks developed
multiple tumors in several organs, such as the kidney and
pancreas (Figure 1Ca), whereas tumor formation was never
observed in nontreated mice (n = 7, 7 months of age). Histolog-
ical analysis revealed that these tumors differentiated into three
different germ layers, indicating that they are teratomas (Fig-
ure 1Cb). When teratoma cells were cultured ex vivo in the
absence of Dox (no additional 4F expressions), iPSC-like cells
were established (Figure 1Da). Importantly, the teratoma-derived
iPSC-like cells contributed to adult chimeric mice when they
were injected into blastocysts (Figure 1Db). Therefore, we(D) Teratomas contain pluripotent stem cells. (a) Ex vivo teratoma culture gave
contributed to adult chimeric mice.
(E) Dysplastic cell expansion by the forced expression of reprogramming factors i
Scale bars, 200 mm (intestine, skin, pancreas, stomach, and gall bladder) and 10
(F) Ki67 immunostaining revealed active proliferation of the dysplastic cells in the
(G) Immunofluorescent staining for Oct3/4 and 2A peptide in the intestine of an O
recognizes both Oct3/4-P2A and Sox2-T2A. Dysplastic cells showed positive st
See also Figure S1.conclude that somatic cells can be reprogrammed in vivo to
pluripotency in our reprogrammable mouse system.
Forced Expression of Reprogramming Factors In Vivo
Leads to Rapid Expansion of Dysplastic Cells
We next examined the early changes after expression of
reprogramming factors in somatic cells in vivo. After treatment
of 4-week-old mice with Dox for 3–9 days, all mice developed
dysplastic lesions in epithelial tissues of various organs (Fig-
ure 1E), although there were variations in severity of the pheno-
type among chimeras. Dysplastic cells proliferated actively, as
revealed by Ki67 staining (Figure 1F). Abnormal proliferation
of somatic cells was observed as early as 3 days after Dox
treatment (Figure S1C), and by day 7, such dysplastic cell
growth was detected even for pancreatic and kidney cells,
which typically do not divide actively under physiological
conditions (Figures 1E and 1F). Immunofluorescent analysis of
Oct3/4 and the 2A peptide (forming transgene connections)
demonstrated that the dysplastic cells expressed repro-
gramming factors (Figure 1G). Collectively, the forced expres-
sion of reprogramming factors caused dysplastic cell expansion
of epithelial tissues in vivo.
The Fate of Early Dysplastic Cells after Withdrawal
of Dox
To examine whether subsequent expansion of such dysplastic
cells depends on the continuous expression of reprogramming
factors, we withdrew Dox for 7 days after an initial 4- to 7-day
treatment (Figure 2A). Although Dox treatment for 4–7 days
caused active cell proliferation in a variety of tissues of all
mice, we did not observe any dysplastic cells in some mice
after withdrawal of Dox (Figure 2A; Table 1). Of particular
note, mice treated with Dox for periods less than 5 days before
withdrawal often revealed a lack of dysplastic cells (Table 1).
These data suggest that early dysplastic cell growth requires
continuous expression of reprogramming factors. We next
investigated the fate of eliminated dysplastic proliferating cells
after the withdrawal of Dox. Bromodeoxyuridine (BrdU) was
injected into mice during Dox treatment to label proliferating
cells caused by reprogramming factor expression during the
first 7 days (Hochedlinger et al., 2005), and then mice were
sacrificed after the withdrawal of Dox for 7 days, on day14.
Notably, BrdU-labeled cells were often observed in normal-
looking pancreatic and kidney tissues at day14 (Figure 2B).
Furthermore, BrdU-labeled cells in the pancreatic islets also
expressed insulin (Figure 2B). This suggests that the expanded
cells caused by the transient expression of reprogramming
factors were, at least in part, integrated into normal-looking
tissues after Dox withdrawal.rise to iPSC-like colonies without Dox exposure. (b) Teratoma-derived iPSCs
n vivo. The histology of various organs of mice treated with Dox for 3 to 9 days.
0 mm (kidney).
pancreas and stomach. Scale bars, 200 mm.
SKM chimeric mouse treated with Dox for 7 days. The 2A antibody used here
aining for both Oct3/4 and 2A. Scale bar, 50 mm.
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Figure 2. Transient Expression of Reprogramming Factors Causes Neoplasia
(A) A schematic drawing of the experiment and histological sections of the pancreas taken on days 7 and 14. Dysplastic cell growthwas induced by treatment with
Dox for 7 days (arrows on day 7). The pancreatic section taken on day 14 revealed normal histology. Scale bars, 200 mm.
(B) Double immunofluorescence for insulin and BrdU in the pancreas on day 14. For the pulse and chase experiment, BrdU was injected intraperitoneally every
day during Dox administration starting on day 2 (days 2–7), followed by withdrawal of Dox for 7 days. BrdU-positive cells were frequently observed in normal-
looking pancreatic islet cells, which also expressed insulin. Scale bar, 100 mm.
(C) Treatment of OSKM chimeric mice with Dox for 7 days, followed by the withdrawal of Dox for another 7 days. Themacroscopic image shows the development
of bilateral kidney tumors on day 14. Representative histological images are shown for Dox-withdrawn tumors in the kidney, pancreas, and liver. Scale bars,
200 mm.
(legend continued on next page)
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Table1. Transient Expression of Reprogramming Factors Causes Tumor Development
Dox Treatment n
Kidney Pancreas Liver
No Phenotype Dysplastic Growth No Phenotype Dysplastic Growth No Phenotype Dysplastic Growth
4 days ON/OFF 4 2 2 4 0 3 1
5 days ON/OFF 2 1 1 2 0 2 0
6 days ON/OFF 5 1 4 2 3 3 2
7 days ON/OFF 33 7 26 22 11 25 8Prolonged Expression of Reprogramming Factors
Leads to Transgene-Independent Tumor Formation
in Somatic Cells
In contrast to the reversion of early dysplastic proliferating cells
into normal-looking cells, mice that had been given Dox for
7 days often went on to develop tumors in multiple responding
organs even after Dox withdrawal (Figure 2C; Table 1). The
developed tumors consisted of histologically undifferentiated
dysplastic cells, which were distinct from teratoma cells (Figures
2C and S2A). The dysplastic cells invaded the surrounding
tissues, which is one of the hallmarks of cancer cell growth
(Figure S2A). Dox-withdrawn tumor cells were negative for 2A
staining, affirming that they grew independent of transgene
expression (Figure S2B). Dox-withdrawn kidney tumors were
similarly observed in elderly mice given Dox starting at 14 weeks
of age (13 out of 19 mice). When Dox-withdrawn kidney tumor
cells were transplanted into the subcutaneous tissues of immu-
nocompromised mice, they formed secondary tumors within
3 weeks without Dox administration (Figures 2D and S2C), re-
flecting the neoplastic potential of Dox-withdrawn tumor cells.
Reprogramming factors in our transgenic system include
c-Myc, a well-known oncogene. To investigate the contribution
of c-Myc on the development of Dox-withdrawn tumors, we
generated three-factor-inducible chimeric mice, which express
Oct3/4, Sox2, and Klf4 (OKS), but not c-Myc, by the targeted
insertion of transgenes into the identical locus as 4F (OSKM)-
inducible mice (Figure 2E). Similar to 4F-induced mice, OKS
induction in vivo caused dysplastic cell growth in various
organs yet required longer periods of treatment (Figure 2E). After
3 weeks of induction of OKS followed by withdrawal for 7 days,
these mice developed the Dox-withdrawn tumors consisting
of undifferentiated dysplastic cells in multiple organs (4 out of
8 mice; Figure 2E). Therefore, transgenic c-Myc is dispensable
for the development of Dox-withdrawn tumors.
Oct3/4 plays a critical role in cellular reprogramming, and
expression of three factors (Klf4, c-Myc, and Sox2) in the
absence of Oct3/4 is not sufficient for iPSC generation (Takaha-
shi and Yamanaka, 2006). To further demonstrate a link between(D) Minced Dox-withdrawn tumor cells were injected in the subcutaneous tissu
phenocopied the original Dox-withdrawn tumor. Scale bars, 200 mm (upper pane
(E) A schematic drawing of the OKS transgene at the Col1a1 locus. A histological
observed in the stomach and kidneys on day 21 (arrows). The dysplastic cell gro
(day 28). Scale bars, 200 mm.
(F) A schematic drawing of the KMS transgene. A histological section of a kidn
for another 7 days (day 14). KMS induction leads to dysplastic growth in the kidne
No dysplastic cells were detectable in the kidneys of KMS-induced mice after th
See also Figure S2.cellular reprogramming andDox-withdrawn tumor development,
we generated chimeric mice in which Klf4, c-Myc, and Sox2
(KMS), but not Oct3/4, can be induced upon Dox treatment
(Figure 2F). Following Dox treatment for 7 days, we observed
dysplastic cell growth in the kidney of KMS-inducible mice
(three out of six mice; Figure 2F). However, in sharp contrast to
OSKM/OKS-induced mice, the withdrawal of Dox eliminated
the dysplastic cells in the kidney of KMS-induced mice (n = 17;
Figure 2F). A previous study demonstrated that ectopic ex-
pression of Oct3/4 alone can induce dysplastic growth whereas
the transgene withdrawal leads to complete reversion of such
dysplasia (Hochedlinger et al., 2005). Consistent with the
previous observation, the Oct3/4-single induction under the
same experimental condition failed to form Dox-withdrawn
tumors (n = 18; Figure S2D). Taken together, we conclude that
reprogramming pressure toward pluripotency driven by the
combination of reprogramming factors is associated with the
development of Dox-withdrawn tumors.
Loss of Cell Identity and Gain of ESC-Related Gene
Expression in Dox-Withdrawn Tumors
To characterize Dox-withdrawn tumor cells, we examined gene
expression in kidney tumors that arose in OSKM-inducible
mice treated with the 7+/7 Dox regimen. In the KH2 system,
transgene expression in the kidney is induced exclusively in
the tubule cells (Beard et al., 2006). We observed decreased
expression of kidney tubule cell-specific genes in Dox-with-
drawn kidney tumors, indicating loss of kidney cell identity
(Figure 3A). A previous study dissected the gene expression
signature of ESCs into three functional modules: core pluripo-
tency factors, Polycomb complex factors, and Myc-related
factors (Kim et al., 2010). Notably, microarray analysis revealed
that the ESC-Core module is similarly activated in Dox-with-
drawn kidney tumors and ESCs (Figure 3B) (Ohta et al., 2013).
We also found that the Myc module displays similar activation
between Dox-withdrawn tumors and ESCs (Figure S3A). The
activation of ESC-Core and ESC-Myc modules was similarly
confirmed in transplanted secondary tumors (Figure S3B).es of immunocompromised mice. A histological section of one of the tumors
l) and 100 mm (lower panel).
section of the kidney on days 21 and 28. The expansion of dysplastic cells was
wth could be detected even after the withdrawal of Dox in OKS-induced mice
ey after the treatment with Dox for 7 days (day 7) and the withdrawal of Dox
y tubule cells (arrows for day 7). The inset shows a higher-magnification image.
e withdrawal of Dox (day 14). Scale bars, 200 mm.
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Figure 3. Loss of Cell Identity and Gain of ESC-Related Gene Expression in the Dox-Withdrawn Tumors
(A) The results of the qRT-PCR analyses ofAqp1 and Lrp2. The expression levels ofAqp1 and Lrp2were significantly downregulated in the Dox-withdrawn kidney
tumors. Data are presented as mean ± SD. The mean level of normal kidney samples was set to 1.
(B) The microarray analyses revealed the activation of the ESC Core module in Dox-withdrawn kidney tumors.
(C) The results of the qRT-PCR analyses of pluripotency-related genes. Data are presented as mean ± SD. The transcript level in ESCs was set to 1.
(D) Lgr5 as a candidate marker of Dox-withdrawn kidney tumor cells. Lgr5 was specifically expressed in Dox-withdrawn kidney tumors. Data are presented as
mean ± SD. The mean level of kidney tumors was set to 1.
(E) A schematic drawing of the experimental protocol using chimeric mice with both reprogrammable alleles and the Lgr5-EGFP allele. Macroscopic images of
the Dox-withdrawn kidney tumor with the Lgr5-EGFP allele showing scattered EGFP signals in the kidney tumor. GFP immunostaining of kidney tumor sections
revealed that the GFP signals are detectable specifically in tumor cells. Scale bar, 100 mm.
(legend continued on next page)
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Some pluripotency-related genes, including Nanog, Oct3/4,
and Lin28a, were upregulated in the Dox-withdrawn kidney
tumor cells as compared to normal kidney tissue, although
the expression levels of both Nanog and endogenous Oct3/4
were significantly lower than that of pluripotent stem cells
(Figures 3C and S3C). Conversely, other pluripotency-related
genes, such as Esrrb, were not upregulated in these tumors
(Figures 3C).
To further characterize Dox-withdrawn tumor cells, we sought
to identify tumor-cell-specific markers. We found that Lgr5 is
specifically upregulated in Dox-withdrawn kidney tumor cells,
but not in adult kidney tissues or pluripotent stem cells (Fig-
ure 3D). Increased expression of Lgr5 was similarly observed
in the transplanted secondary tumors (Figure S3D). Therefore,
we established iPSC lines from OSKM-inducible MEFs contain-
ing Lgr5-EGFP reporter allele in which Lgr5 expression can
be visualized by enhanced green fluorescent protein (EGFP)
(Barker et al., 2007). The established Lgr5-reporter iPSCs do
not express EGFP in ESC culture conditions (Figure S3E).
OSKM-inducible Lgr5 reporter chimeric mice at 4 weeks of
age were treated with the 7+/7 Dox regimen. Again, these
mice developed Dox-withdrawn kidney tumors consisting of
dysplastic cells (Figure 3E). The scattered EGFP signals were
observed in kidney tumors (Figure 3E), and immunohistochem-
ical analysis revealed that Lgr5 is specifically expressed in part
of Dox-withdrawn kidney tumor cells (Figures 3E and S3E).
These findings indicate that Dox-withdrawn kidney tumors
contain Lgr5-positive cells and that the Lgr5 reporter allele is
available to specifically identify the Dox-withdrawn kidney tumor
cells that are distinct from fully reprogrammed pluripotent stem
cells. Of note, some of the Lgr5-expressing tumor cells also
expressed Oct3/4 and Lin28b in immunohistochemical analysis
(Figures 3F and S3F), thus suggesting that Lgr5-expressing
tumor cells share some characteristics with pluripotent stem
cells. The fact that Dox treatment for longer than 8 days followed
by Dox withdrawal often results in teratoma formation supports
the notion that partial reprogramming toward pluripotent stem
cells is involved in the development of Dox-withdrawn tumors
(data not shown). Altogether, our findings indicate that Lgr5-
expressing tumor cells are distinct from pluripotent stem cells
but contain partially reprogrammed cells.
Failed Repression of ESC-Polycomb Targets
in Dox-Withdrawn Tumors
In contrast to ESC-like activation observed for both the ESC-
Core and ESC-Myc modules, the ESC Polycomb repressive
complex (PRC) module was differentially expressed between
Dox-withdrawn tumors and ESCs (Figure 4A). We found that a
number of ESC-PRC targeted genes are not repressed in both
kidney tumors and transplanted secondary tumors (Figures 4A,
S4A, and S4B), indicating that the failed repression of ESC-
PRC targets is associated with the development of Dox-with-(F) Dox-withdrawn tumors express pluripotency-related proteins. Double immuno
cells also expressed Lin28b. Double immunofluorescence for Oct3/4 and GFP (L
nucleus. Scale bars, 20 mm.
See also Figure S3.drawn tumors. Consistent with the notion, more than one-forth
of the upregulated genes in tumor cells as compared to ESCs
(greater than 3-fold upregulation) were targets of PRC in ESCs
(Mikkelsen et al., 2007) (Table S1). We also found that Dox-
withdrawn kidney tumors express kidney-precursor-expressing
genes such as Six2, Eya1, and Lgr5 (Barker et al., 2012; Kobaya-
shi et al., 2008) (Figures 4B andS4C). In particular, Six2 and Lgr5,
which are also PRC targets in ESCs (Mikkelsen et al., 2007), are
specifically upregulated in both Dox-withdrawn kidney tumors
and secondary tumors when compared to both normal kidney
tissues and pluripotent stem cells (Figures 3D, 4B, S3D, and
S4D). Chromatin immunoprecipitation (ChIP)-qPCR experiments
confirmed decreased H3K27me3 levels at both Six2 and Lgr5
promoter regions in Dox-withdrawn tumors when compared
with those in normal kidney tissues (Figure S4E). Failed repres-
sion of the ESC-PRC module was also detectable in unsuccess-
fully reprogrammed kidney cells in vitro, which were established
by the transient expression of reprogramming factors in isolated
kidney tubule cells in vitro (Figure S4F).
We next examined the kinetics of transcriptional changes
during the development of the Dox-withdrawn tumors. Immu-
nohistochemical analysis revealed that early dysplastic cells at
day 7 coincide with transgene-expressing cells (Figure S4G).
Taking advantage of florescence-linked transgene expression
in our mice, we fluorescence-activated cell sorted mCherry-
positive kidney cells in OSKM mice given Dox for 7 days (D7),
isolating early dysplastic cells for gene expression analysis.
Fluorescence-activated cell-sorted D7 LacZ-mCherry-express-
ing kidney cells were used as a control (Figure S4H). Decreased
expression of proximal tubule cell markers was observed in
the D7 OSKM cells as compared to D7 LacZ cells, suggesting
that the loss of kidney cell identity occurs in early dysplastic
cells (Figure S4I). In contrast, increased expression of ectopic
stem/progenitor cell markers was not evident in D7 OSKM
cells (Figure S4I). These findings suggest that remodeling of
global transcriptional profiles toward a stem/progenitor-like
state is specifically associated with transgene-independent,
late dysplastic cells.
To investigate cell-of-origin effects on failed reprogramming,
we next performed a microarray analysis for Dox-withdrawn
liver tumors and compared the data with that of kidney tumors.
As observed in kidney tumors, the liver tumors displayed
failed repression of the ESC-PRC module, accompanied by
activation of both the ESC-Core and Myc modules (Figure S4J;
Table S1). Although derepressed PRC module genes in
kidney tumors and liver tumors often overlapped (Figure S5A;
Table S1), we found differentially derepressed PRC genes
between kidney and liver tumors. Notably, such differentially
derepressed PRC genes were associated with kidney and
liver development, respectively. These findings suggest that
failed PRC repression in Dox-withdrawn tumors may be
associated with the activation of a developmental transcriptionfluorescence for Lin28b and GFP (Lgr5) revealed that the GFP-positive tumor
gr5) showed that a subset of GFP-positive tumor cells expressed Oct3/4 in the
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Figure 4. Altered Epigenetic Regulation in Dox-Withdrawn Tumors
(A) The microarray analyses revealed that ESC-PRC target genes were often activated in Dox-withdrawn kidney tumors compared to normal kidney tissues.
(B) Six2 was highly expressed only in the Dox-withdrawn kidney tumors. Data are presented as mean ± SD. The mean level of kidney tumors was set to 1.
(C) Altered DNA methylation patterns in Dox-withdrawn tumors and the DNA methylation status of representative genes in the RRBS analyses.
(D) The global analyses for the DNA methylation levels. Genes that were differentially methylated between ESCs and normal kidney samples (more than 30%
difference) were extracted and then analyzed for DNA methylation levels in Dox-withdrawn kidney tumors. Kidney tumors gain DNA methylation at ESC-
methylated genes, whereas kidney-methylated genes often retain their methylation status in kidney tumors.
(legend continued on next page)
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program, which is affected in part by the cell of origin
(Figure S5A).
Altered DNA Methylation in Dox-Withdrawn
Kidney Tumor Cells
Somatic cell reprogramming is accompanied by global changes
in DNA methylation patterns (Mikkelsen et al., 2008). The fact
that failed reprogramming can cause tumor development
suggests that altered epigenetic modifications play a role in
tumorigenesis. To quantitatively profile DNA methylation in
Dox-withdrawn tumors, we next performed reduced represen-
tation bisulfite sequencing (RRBS) (Meissner et al., 2005). We
identified a number of genes with altered DNA methylation
levels in Dox-withdrawn tumors as compared to normal kidney
tissues. Dox-withdrawn tumors revealed frequent gains of
DNA methylation at DNA-methylated genes in ESCs, whereas
loss of methylation at DNA-methylated genes in kidney tissues
was not evident (Figure 4C). To validate these findings, we
next performed a global analysis. We first extracted genes
differentially methylated between ESCs and normal kidney
samples and then examined their DNA methylation in Dox-
withdrawn tumors. The global analysis confirmed that Dox-
withdrawn kidney tumors gained de novo methylation at
ESC-methylated genes, whereas kidney-methylated genes
often retain their methylation in Dox-withdrawn kidney tumors
(Figure 4D). Consistent with these findings, ESC-methylated
genes were frequently found to be repressed in Dox-withdrawn
tumors, whereas kidney-methylated genes tended to remain
silent in these tumors (Figure 4E). These results suggest that
loss of somatic cell-specific DNA methylation is preceded by
a gain of ESC-specific DNA methylation patterns during the
reprogramming process.
Adult cancers generally exhibit two distinct patterns of alter-
ations in DNA methylation: site-specific DNA hypermethylation
and global DNA hypomethylation (Jones and Baylin, 2002; Ya-
mada et al., 2005). We performed specified regional analyses
for the DNA methylation in normal kidney tissues and Dox-with-
drawn kidney tumors. DNA hypermethylation at promoter re-
gions in Dox-withdrawn tumors was not detectable, regardless
of the presence of CpG islands (Figure S5B). Additionally,
decreased DNA methylation levels at intergenic regions were
not obvious in Dox-withdrawn tumors (Figure S5B).
We found that Dox-withdrawn kidney tumors aberrantly ex-
press a number of imprinted genes and that altered expression
levels are similar to those in ESCs (Figure S5C). When DNA
methylation status at differentially methylated regions (DMRs)
of imprinted genes were examined in Dox-withdrawn tumors
using a MassARRAY platform (Ehrich et al., 2005), we found
frequent alterations of DNA methylation status at DMRs in
Dox-withdrawn tumors (Figure S5D). The aberrant genomic
methylation levels at imprinted genes in Dox-withdrawn tumors(E) DNA-methylation-associated gene regulation in Dox-withdrawn tumors. The v
tumors, whereas a significant portion of kidney-methylated genes remained repre
in ESCs and kidney-methylated genes with decreased expression levels in the k
(F) Altered DNA methylation at the DMR of imprinting genes. Note that kidney
In contrast, kidney tumor 1 showed an aberration only at Nnat.
See also Figures S4 and S5.were also confirmed by RRBS analysis (Figures 4F and S5E).
Intriguingly, each Dox-withdrawn tumor revealed variable aber-
rations in DNA methylation at different imprinted genes. The
aberrant methylation includes hypermethylation at the Meg3
(Gtl2) DMR, which has been correlated with impaired differen-
tiation properties of iPSCs (Stadtfeld et al., 2010a) (Figures 4F
and S5E). Moreover, SNP analysis in the hybrid KH2 background
revealed that the altered expression of some imprinted genes
in Dox-withdrawn tumors arise from biallelic transcription,
compared to monoallelic expression in the original OSKM-
inducible ESCs (Figure S5F). Collectively, these results suggest
that genomic imprinting is unstable in Dox-withdrawn tumors
and provide additional evidence that altered gene expression
underlying tumor development is associated with altered epige-
netic signatures.
Dox-Withdrawn Kidney Tumors Resemble Wilms
Tumors
Histological analysis revealed that Dox-withdrawn kidney
tumors in reprogrammable mice resemble Wilms tumor, the
most common pediatric kidney cancer (Figure 5A). A number
of studies demonstrated that increased expression of Igf2 with
DNA hypermethylation at the H19 DMR is one of the causative
and most common alterations in Wilms tumors (Ogawa et al.,
1993; Steenman et al., 1994). We confirmed that Dox-withdrawn
tumors express a significantly higher level of Igf2 than nonin-
duced tissues (Figures 5B and S6A). Moreover, consistent with
altered DNAmethylation at other imprinted genes, the increased
methylation at the H19 DMR was detectable in some Dox-with-
drawn kidney tumors (Figure 5C).
To additionally evaluate the similarity between Dox-withdrawn
kidney tumors and Wilms tumors, we next compared global
gene expression patterns. We first selected genes that are
upregulated more than 5-fold in Dox-withdrawn kidney tumors
in comparison with noninduced kidney tissues and then as-
sessed expression of their human orthologs in human normal
kidney tissues, Wilms tumors, and human ESCs (hESCs) using
previously reported microarray data sets (Tchieu et al., 2010;
Yusenko et al., 2009). We found that upregulated genes in
Dox-withdrawn kidney tumors are frequently upregulated in
both Wilms tumors and hESCs as compared to normal kidney
samples (Figure 5D), whereas this upregulation is not evident in
adult kidney cancers (renal cell carcinomas [RCCs]) (Figure S6B).
We also analyzed the expression of genes in ESC-Core,
ESC-Myc, and ESC-PRC modules in Wilms tumors. Notably,
ESC-upregulated genes in both ESC-Core and ESC-Myc mod-
ules are similarly activated in Wilms tumors (Figures 5D and
S6C), although NANOG and OCT3/4 are not expressed in Wilms
tumors. In contrast, a fraction of ESC-PRC targeted genes
expressed in kidney progenitors, such as SIX2 and LGR5, are
specifically upregulated in Wilms tumors as compared withast majority of ESC-methylated genes were downregulated in Dox-withdrawn
ssed in these tumors. ESC-methylated genes with decreased expression levels
idney tissues were examined.
tumor 2 showed aberrant methylation patterns at Nnat, Impact, and Meg3.
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Figure 5. Dox-Withdrawn Kidney Tumors Resemble Wilms Tumors
(A) Representative histological findings of Dox-withdrawn kidney tumors (a–d). Tumors consisted of epithelial (b), stromal (c), and blastema-like (d) compart-
ments, which are histological features of Wilms tumors. Scale bars, 500 mm (a) and 100 mm (b–d).
(B) The results of the qRT-PCR analysis for Igf2. Igf2 was highly expressed in Dox-withdrawn kidney tumors. Data are presented as mean ± SD. The mean level
of kidney tumors was set to 1.
(legend continued on next page)
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those in normal kidney tissues, hESCs, and RCCs (Figures 5D
and S6D) (Aiden et al., 2010). Collectively, kidney tumors
induced by the transient expression of reprogramming factors
display a number of shared characteristics with Wilms tumor.
These findings also indicate that our mouse model may prove
useful to uncover the pathogenesis of Wilms tumors.
iPSCs Derived from Dox-Withdrawn Kidney Tumors
Contribute to Nonneoplastic Kidney Tissues in
Chimeric Mice
We next tried to establish iPSCs from Dox-withdrawn kidney
tumor cells. The tumor cell-specific Lgr5-EGFP reporter allele
defined in this study was utilized to isolate tumor cells (Figures
3D, 3E, and S3E). Lgr5-expressing GFP-positive tumor cells
were sorted and cultured in vitro with Dox to establish iPSCs
from tumor cells (Figure 6A). During the culture of Lgr5-express-
ing tumor cells in vitro, Nanog expression at a level comparable
to that in pluripotent stem cells was detected as early as 7 days
after reprogramming factor induction (Figure 6B), a rate faster
than the reprogramming process from normal kidney tubule cells
in vitro (Figure S7A). After 2 weeks of culture with Dox exposure,
more than 20 alkaline phosphatase (AP)-positive iPSC-like
colonies were obtained from 100 Lgr5-expressing tumor cells
(Figure S7B). We were able to establish Dox-independent iPSC
lines from tumor cells at 3 weeks after transgene induction
(Figure 6C), suggesting that the Dox-withdrawn tumor cells can
be readily reprogrammed into pluripotent stem cells.
Cancers are believed to arise through the accumulation of
multiple genetic abnormalities. We next investigated whether
genetic abnormalities mandate the emergence of in Dox-with-
drawn tumors. Exonic regions of 514 genes that include
human-cancer-related genes in transplanted secondary kidney
tumors were sequenced using a hybridization selection tech-
nique combined with next-generation sequencing (Table S3).
Mutations in Wt1, Wtx, Ctnnb1, and Trp53, all of which have
been identified in a subset of Wilms tumors, were not detected
in three tumors examined. In addition, no cancer-related gene
mutations were enriched in these tumors (data not shown).
Array-based comparative genomic hybridization (CGH) re-
vealed no prevalent chromosomal alteration in tumor samples
(Figure S7C).
Finally, we injected the tumor-derived iPSCs into blastocysts
to generate chimeric mice. Tumor-derived iPSCs contributed
into adult chimeric mice (Figure 6D). Notably, the kidney-tumor-
derived iPSCs differentiated into normal-looking kidney tissues
(Figures 6E, 6F, and S7D). Moreover, these chimeric mice did
not develop tumors even at 24 weeks of age (n = 8). To further
demonstrate that tumorigenic cells can be reprogrammed into
nonneoplastic cells, we also established iPSCs from the trans-
planted secondary tumors and confirmed their contribution to
nonneoplastic kidney tissues (Figure S7E). These results sub-
stantiate that a genetic context of the Dox-withdrawn kidney
tumor cells is not determinant of the cancer phenotype and(C) The bisulfite sequencing analysis revealed increased DNA methylation levels
(D) The results of the global expression analyses in Wilms tumors. The human ort
were assessed using previously reported microarray data sets (GSE11151 and G
See also Figure S6.support the conclusion that altered epigenetic regulations cause
the abnormal growth in somatic cells, leading to the develop-
ment of Dox-withdrawn tumors.
DISCUSSION
During somatic cell reprogramming, iPSCs gain the capacity
for unlimited growth without particular genetic alterations. Using
abbreviated reprogramming factor expression in vivo, we
demonstrate that transient expression of reprogramming factors
leads to tumor development. Such tumors display altered
epigenetic modifications, indicating that epigenetic regulation
characteristic of cellular reprogramming may also confer
neoplastic growth properties to somatic cells. Intriguingly,
Dox-withdrawn tumor cells are readily reprogrammed into
pluripotent stem cells by additional 4F expression, indicating
that the tumor cells represent a cellular state closer to iPSCs
than the original somatic cells. Moreover, kidney tumor cell-
derived iPSCs contribute to various somatic cell types and
give rise to nonneoplastic kidney cells in mice. These data
demonstrate that the abnormal growth of unsuccessfully reprog-
rammed cells depends predominantly on epigenetic regulations
and raise the possibility that particular types of cancer may arise
exclusively through altered epigenetic regulation.
Histological features of Dox-withdrawn tumors imply that
unsuccessfully reprogrammed cells lack the ability to terminal
differentiate along multiple lineages. It is noteworthy that Dox-
withdrawn tumor cells fail to repress ESC-PRC targets yet share
the activation of ESC core regulatory circuitry and Myc-related
genes with pluripotent stem cells. It is conceivable that the
repression of ESC-PRC targets would be exclusively associated
with the acquisition of pluripotency, whereas activation of ESC
core regulatory circuitry and Myc targets lead to self-renewing
activity. This notion is also consistent with previous findings
that PRC components are important for successful repro-
gramming in humans (Onder et al., 2012). Notably, the failed
repression of the ESC-PRCmodule was detectable in previously
reported partially reprogrammed cells in vitro (Polo et al., 2012),
in which the activation of both ESC-Core and ESC-Myc modules
had already occurred (Figure S7F). We also found that unsuc-
cessfully reprogrammed kidney cells tend to retain DNA methyl-
ation at kidney-specific methylated genes. Considering that
global epigenetic reorganization, including changes in both
H3K27methylation and DNAmethylation, occurs during the later
phase of iPSC generation (Polo et al., 2012), the expected
repression of ESC-PRC targets and demethylation of somatic
cell-specific genomic methylation might play a role in the final
stages of successful somatic cell reprogramming.
Recently, Abad et al. reported that in vivo reprogramming
allows the acquisition of totipotent features resulting in em-
bryo-like cyst formation in reprogrammable mice (Abad et al.,
2013). However, in the present study, we did not observe
such cystic structures in Dox-treated reprogrammable mice.at the H19 DMR containing two CTCF binding sites in Dox-withdrawn tumors.
hologs of upregulated genes in Dox-withdrawn tumors and ESC module genes
SE22246).
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Figure 6. Generation of iPSCs from Dox-Withdrawn Tumors and Their Contribution to Normal-Looking Kidney Tissue
(A) The fluorescence-activated cell sorting analyses of Dox-withdrawn kidney tumor cells in a reprogrammable chimeric mouse with the Lgr5-EGFP reporter.
GFP-positive Lgr5-expressing cells were sorted to exclusively isolate Dox-withdrawn tumor cells.
(B) Dox treatment of Lgr5-expressing tumor cells caused the rapid induction of Nanog. The Nanog levels were examined after seven days of treatment with Dox
in vitro. Data are presented as mean ± SD. The level in ESCs was set to 1.
(C) An image of iPSCs derived from Lgr5-positive kidney tumor cells.
(legend continued on next page)
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Furthermore, teratoma-derived in vivo iPSCs in this study failed
to differentiate into placental tissues despite robust fetal contri-
bution upon injection into eight-cell-stage embryos (data not
shown), suggesting that not all in vivo iPSCs are totipotent.
Because the previous study was conducted using circulating
iPSCs recovered in blood, the cell of origin for in vivo reprogram-
ming might affect the acquisition of totipotent features. It should
be also noted that Abad et al. utilized germline-transmitted trans-
genic mice that harbor lentivirus-mediated integration of induc-
ible reprogramming factors (Carey et al., 2009) whereas we
examined chimeric mice with transgenes at a targeted locus.
The different levels of transgene induction caused by such
distinct transgenic systems may underlie differences in the phe-
notypes observed between these two studies.
Here, we show that failed reprogramming-associated can-
cers resemble Wilms tumors in terms of histology and molecu-
lar characteristics, including aberrant expression of imprinted
genes correlated with altered DNA methylation. It is well known
that Wilms tumors have characteristics distinct from adult kid-
ney cancers in many aspects. On the basis of our findings in
Dox-withdrawn tumors, we discovered that Wilms tumors
harbor an activated ESC core regulatory circuitry. This is in
sharp contrast to previous findings that most adult cancers
do not show activation of ESC core regulatory circuitry (Kim
et al., 2010). We also found that many ESC-PRC targets are
not repressed in Wilms tumors, despite common repression
in many cancers (Ben-Porath et al., 2008; Kim et al., 2010).
Gene Ontology analysis revealed that derepressed PRC genes
in Wilms tumors include genes involved in kidney development,
whereas they are not enriched in derepressed PRC genes in
RCCs (data not shown), suggesting that activation of the em-
bryonic kidney transcriptional network is associated with Wilms
tumor development. Taken together, strongly active ESC-core
regulatory circuitry and derepression of certain ESC-PRC tar-
gets may characterize Wilms tumors and may account for the
characteristics distinctive of Wilms tumors and adult kidney
cancers.
Although we revealed striking similarity between Dox-with-
drawn kidney tumors and Wilms tumors, it remains unclear
whether reprogramming processes play a role in the develop-
ment of human Wilms tumors. It has been widely accepted
that nephrogenic rests, abnormally persistent clusters of embry-
onal cells, are the precursors of Wilms tumors. Considering the
artificial expression of reprogramming factors in our experi-
mental system, the current study does not provide direct
evidence that dedifferentiation is normally involved in the
human Wilms tumor development. Yet, based on our findings,
it is conceivable that a reprogramming process might cause
cell-fate conversion into progenitor-like states, leading to the
development of nephrogenic rests required for the early stages
of Wilms tumorigenesis. Further detailed analyses using human(D) Kidney tumor-derived iPSCs can contribute to adult chimeric mice.
(E) No tumor formationwas observed in the kidneys of chimeric mice generatedwi
contribution of kidney-tumor-derived iPSCs to the normal-looking kidney.
(F) The histological analyses of the kidneys of chimeric mice demonstrated no
labeled with Venus could contribute to normal-looking kidney (c). Scale bars, 50
See also Figure S7.samples are required to uncover the role of reprogramming in
cancer development in humans.
In summary, we demonstrated that premature termination of
in vivo reprogramming causes tumor development resembling
Wilms tumor. Our findings suggest that altered epigenetic
regulations relating to somatic cell reprogramming drive tumori-
genesis, highlighting the importance of epigenetic regulation in
cancer development.
EXPERIMENTAL PROCEDURES
Generation of OSMK-Inducible ESCs
A 7 kb fragment containing Oct3/4-P2A-Sox2-T2A-Klf4-E2A-c-Myc-ires-
mCherry cDNA was generated (Carey et al., 2009) and ligated into the
pBS31 vector (Beard et al., 2006). The resulting construct was electroporated
into KH2 ESCs to obtain OSKM-inducible ESCs (Beard et al., 2006). OKS-,
KMS-, O-, LacZ-inducible ESCs were also generated using the KH2 ESCs
system.
Mice
Chimeric mice were generated using reprogramming factor-inducible ESCs
by diploid blastocyst injection. Lgr5-EGFP-ires-CreERT2 mice were obtained
from The Jackson Laboratory and were crossed with OSKM-inducible mice
to obtain embryos. The compound transgenic MEFs were treated with Dox
to establish the OSKM-inducible iPSCs with the Lgr5-EGFP reporter allele.
All animal experiments were approved by the CiRA Animal Experiment
Committee, and the care of the animals was in accordance with institutional
guidelines.
Doxycycline Treatment
Mice at 4 or 14 weeks of age were administered 2 mg/ml Dox in their drinking
water supplemented with 10 mg/ml sucrose. For cell culture, Dox was used at
a concentration of 2 mg/ml.
Secondary Tumor Development
Primary kidney tumors were minced and treated with collagenase (1 U/ml)
followed by 0.25% trypsin digestion. The dissociated tumor cells were inocu-
lated subcutaneously into BALB/cSlc-nu/nu mice or C.B-17/Icr-scidJcl mice
to form transplanted secondary tumors.
RNA Preparation, qRT-PCR and Microarray Analysis
Total RNA was isolated using the RNeasy Plus Mini kit (QIAGEN). The quanti-
tative real-time PCR analysis was performed using the GoTaq qPCR Master
Mix (Promega). The specific primer pairs used for amplification are shown
in Table S2. The transcript levels were normalized to the b-actin level. The
microarray analysis was performed using the Mouse Gene 1.0 ST Array
(Affymetrix) in accordance with the manufacturer’s instructions. All of the
data analyses were performed using the GeneSpring GX software program
(version 12; Agilent Technology).
DNA Methylation Analyses
The RRBS analysis was performed as described previously (Boyle et al., 2012).
The samples were sequenced on an Illumina HiSeq 2000 machine. Three-kilo-
base regions flanking transcription start site (from 1,500 to +1,500) were
analyzed to examine DNA methylation levels. The DNA methylation levels for
each gene were determined based on the median of DNA methylation values
at CpG sites within the region. The DNA methylation values at CpG sitesth kidney tumor-derived iPSCs. Note that Dox treatment for 24 hr confirmed the
detectable histological abnormalities (a and b). Kidney-tumor-derived iPSCs
0 mm (a) and 100 mm (b, c).
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containing higher than 103 coverage in all comparative samples were used
for the analysis.
Histological Analysis and Immunostaining
Normal and tumor tissue samples were fixed in 10% buffered formalin for
24 hr and embedded in paraffin. Sections (4 mm)were stainedwith hematoxylin
and eosin (H&E), and serial sections were used for the immunohistochemical
analyses. The primary antibodies used were anti-Oct3/4 (1:100 dilution; BD
Biosciences), anti-Ki-67 (1:100 dilution; Dako), anti-insulin (1:500 dilution;
Dako), anti-BrdU (1:500 dilution; Abcam), anti-2A (1:250 dilution; Millipore),
anti-Lin28b (1:100 dilution; Cell Signaling Technology), and anti-GFP (1:500
dilution; Invitrogen).
ACCESSION NUMBERS
The Gene Expression Omnibus accession number for the microarray and
RRBS data reported in this paper is GSE52304.
SUPPLEMENTAL INFORMATION
Supplemental Information includes Extended Experimental Procedures,
seven figures, and three tables and can be found with this article online at
http://dx.doi.org/10.1016/j.cell.2014.01.005.
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